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75 g oral glucose tolerance test (OGTT)
A B S T R A C T
Aims/hypothesis: To determine the impact of implementing the new WHO-2013 criteria on prevalence of
gestational diabetes mellitus (GDM) and pregnancy outcomes compared to the WHO-1999 criteria.
Methods: A retrospective study conducted in pregnant women who were referred to the Erasmus MC for
an oral glucose tolerance test (OGTT) between 2010 and 2015.
Results: Of 3089 women, 11.5 % (n = 354) were diagnosed with GDM based on the WHO-1999 criteria and
17.0 % (n = 524) based on the 2013–criteria, with 97 (3.1 %) reclassified as non-GDM and 267 (8.6 %)
reclassified as GDM when shifting from the 1999 to 2013-criteria. In contrast to 60 % of patients in the
WHO-2013 group, only 2 % of the WHO-1999 group was diagnosed with GDM because of an elevated
fasting glucose only. Patients reclassified as GDM by WHO-2013 criteria had a higher body mass index
(p < 0.001) and delivered babies with a higher birth weight (p = 0.01). Maternal and neonatal adverse
outcomes were comparable between patients with GDM based on WHO-1999 criteria and patients newly
included by WHO-2013 criteria.
Conclusions: Implementing the new diagnostic criteria leads to a considerable increase of prevalence of
GDM. The newly included patients were more frequently overweighed and delivered babies with a higher
birth weight. The added diagnostic value of the fasting glucose threshold of the WHO-1999 criteria is very
low compared to the 2-h post-OGTT threshold, supporting the use of a lower fasting glucose threshold
value as advocated by the WHO-2013 criteria.
Tweet: The new WHO-2013 criteria leads to a considerable increase of prevalence of GDM.
© 2019 Published by Elsevier B.V.
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Gestational diabetes mellitus (GDM) is defined as new onset or
first recognition of abnormal glucose tolerance during pregnancy
[1]. The estimated prevalence of GDM in the Netherlands varies
between 2–5 % [2]. Due to the rising epidemic of overweight,
obesity and increase in mean maternal age the prevalence of GDMAbbreviations: BMI, body mass index; CS, caesarean section; DM, diabetes
mellitus; GDM, gestational diabetes mellitus; HAPO, Hyperglycemia and Adverse
Pregnancy Outcomes study; IADPSG, The International Association of the Diabetes
and Pregnancy Study Groups; LGA, large for gestational age; NICU, neonatal
intensive care unit; OGTT, oral glucose tolerance test; PE, preeclampsia; PIH,
pregnancy induced hypertension; SGA, small for gestational age; WHO, World
Health Organization.
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Erasmus Medical Centre, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
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https://doi.org/10.1016/j.ejogrb.2019.12.013
0301-2115/© 2019 Published by Elsevier B.V.is rising and constitutes the most common metabolic complication
during pregnancy [3–5].
Among the main consequences of GDM are increased risks of
preeclampsia (PE), macrosomia and cesarean delivery and their
associated morbidities [6]. In addition, higher placental passage of
glucose can result in postnatal hyperinsulinemia and hypoglyce-
mia in newborn infants potentially compromising neurodevelop-
mental outcomes [6]. Identifying pregnant women with GDM
followed by frequent glucose monitoring and appropriate treat-
ment, including dietary advices and/or insulin therapy and/or
other glucose lowering medication, has reported to be associated
with a decrease in macrosomia, shoulder dystocia, and PE [6].
Since GDM is mostly asymptomatic, laboratory screening is
required for its detection. The Dutch Society of Obstetrics and
Gynecology (NVOG) recommends screening at 24–28 weeks of
gestation in pregnant women with risk factors for developing GDM
and a first screening at 16 weeks gestation in women with a history
of GDM [7,8].
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diagnose GDM. The NVOG recommends a 75 g OGTT using the
cut-off values of the World Health Organization (WHO) published
in 1999: a fasting plasma glucose level (FG) 7.0 mmol/L or a 2-h
plasma glucose level (2 h G) of 7.8 mmol/L [7,8]. Following the
HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes),
the International Association of the Diabetes and Pregnancy
Study Groups (IADPSG) proposed new diagnostic criteria for
GDM: FG  5.1 mmol/L, 1-hr level of  10 mmol/l or a 2 h G
level 8.5 mmol/L [9]. Subsequently, the WHO adopted these new
diagnostic criteria for GDM in 2013 [10]. Compared to the
WHO-1999 criteria, the WHO-2013 criteria are based on a
considerably lower threshold for fasting but a higher threshold
for the 2 -h post loading glucose level.
The WHO-2013 criteria have not been implemented in the
Netherlands yet. In a retrospective study, we investigated the
consequences of applying WHO-2013 criteria on the prevalence of




A retrospective study was conducted of patients who under-
went a 75-g OGTT from June 2010 to September 2015 at the
Erasmus MC. Patients were referred by their midwife or by their
gynecologist for a 75-g OGTT if they had one or more risk factors for
GDM according to the Dutch national guideline [7]. Pregnant
women with an abnormal OGTT according to the WHO-1999
criteria or the WHO-2013 criteria were eligible for analysis.
Importantly, because GDM according to WHO-2013 was diagnosed
retrospectively only women with a disturbed OGTT according to
the WHO-1999 criteria were treated for GDM. Women with pre-
existing diabetes, twin pregnancy and a delivery outside of the
Erasmus MC were excluded.
Measurements
Plasma glucose measurements were performed at the clinical
laboratory of the Erasmus MC. Plasma glucose was measured by an
enzymatic hexokinase method (Roche/Hitachi cobas c systems,
Manheim, Germany).
Outcomes and definitions
Data on maternal characteristics, pregnancy and fetal outcomes
were retrospectively collected from the patients’ records. All data
were incorporated in an anonymized database.
Maternal characteristics were age, parity, pre-gestational body
mass index (BMI), positive family history of diabetes mellitus
(DM), history of GDM, HbA1c levels and gestational age at OGTT.
The maternal outcomes were the following: HbA1c levels of the
mother at time of diagnosis and delivery, treatment of GDM
(dietary advices, insulin, oral medication or a combination),
pregnancy induced hypertension (PIH) (systolic blood pressure
140 mmHg and/or a diastolic blood pressure 90 mmHg after 20
weeks of gestation in a previously normotensive woman),
preeclampsia (PE) (gestational or pre-existing hypertension with
de novo proteinuria (>300 mg/24 h), mode of delivery (vaginal
delivery, instrumental delivery, primary caesarean section (CS) or
secondary CS).
The fetal outcomes were the following: birth weight (grams),
small for gestational age (SGA; birth weight <10th percentile
corrected for gestational age, sex and parity), large for gestational
age (LGA; birth weight >90th percentile corrected for gestationalage, sex and parity), prematurity (delivery <37 weeks of gestation),
shoulder dystocia, hyperbilirubinemia requiring phototherapy,
neonatal hypoglycemia (blood glucose level <2.6 mmol/L at least
3 h postpartum), admission to the neonatal intensive care unit
(NICU), birth defects, need for respiratory support and mortality
(intra-uterine or postpartum).
Statistical analysis
IBM SPSS Statistics 24 was used for the statistical analysis. The
normality of continuous variables was assessed using the Shapiro-
Wilk W-test. Continuous data between >2 groups were compared
using ANOVA in case of normal distribution, the Kruskal Wallis in
case of skewed distribution, with the Bonferroni correction in case
of multiple comparisons. The chi-square test was used to compare
categorical data among the groups. A p value less than 0.05 was
considered statistically significant. Continuous variables are




A total of 3165 OGTT’s were carried out in 3089 subjects from
June 2010 to September 2015. Thirteen patients with an abnormal
OGTT according to the WHO-1999 criteria or the WHO-2013
criteria (respectively five and eight) had to be excluded from
analysis due to lost to follow-up.
The prevalence of GDM was 11.5 % (n = 354) according to the
WHO-1999 criteria, increasing to 17.0 % (n = 524) when the WHO-
2013 criteria were used. When shifting from old to new criteria, 97
women were reclassified as non-GDM (WHO-2013 excluded) and
267 women were reclassified as GDM (WHO-2013 included).
According to the WHO-1999 criteria 98 % of patients were
diagnosedwith GDM becauseof an elevated2-handonly 2 % because
of both an elevated fasting and 2-h post OGTT plasma glucose level.
Consequently, all women diagnosed with GDM had an elevated 2-h
post OGTT plasma glucose level. In the WHO 2013 group, 58 % was
diagnosed with GDM because of an elevated fasting plasma glucose,
21 % because of an elevated 2-h plasma glucose and 21 % because of
both an elevated fasting glucose and 2-h glucose (Fig. 1). Conse-
quently 79 % could be diagnosed with GDM using a fasting plasma
glucose level only when using the WHO-2013 criteria.
Characteristics
Age among the three groups was similar as was the history of
GDM (Table 1). Women reclassified as non-GDM according to the
WHO-2013 criteria were more often nulliparous than women
reclassified as GDM (p = 0.02). The pregestational BMI of women
who were reclassified as GDM was higher (p < 0.001) than that of the
two other groups (Table 1). HbA1c levels were lower (p < 0.001) in
the WHO-2013 excluded group than in the WHO-1999 group.
The majority of the WHO-2013 included group were not treated
for GDM, but treatment modalities for GDM between the WHO-
1999 and WHO-2013 group did not differ (Table 2). Gestational age
at delivery among the three groups was similar as was the mode of
delivery and occurrence of PE (Table 2). Cesarean sections were less
often based on a maternal indication in the WHO-2013 excluded
group. The birth weight in the newly included group was
moderately higher than in the two other groups (Table 3), but
the proportions of LGA neonates among the three groups did not
differ. There were no differences between the groups in the
prevalence of prematurity, shoulder dystocia, hyperbilirubinemia













N 354 97 267 – – –
Age, years 34 (20–47) 32 (20–45) 33 (18–46) 0.177 0.999 0.731
Nulliparous 116 (32.8) 39 (40.2) 72 (27.0) 0.185 0.134 0.020*
Pregestational BMI, kg/m2 26.8 (17–69) 25.6 (17–45) 29.8 (14–61) 0.223 <0.001* <0.001*
Positive family history of DM, n (%) 161 (45.9) 37 (38.1) 108 (41.1) 0.204 0.250 0.630
History of GDM, n (%) 39 (11.1) 8 (8.3) 36 (13.5 %) 0.463 0.386 0.207
Gestational age at OGTT, weeks 28 (8–40) 27 (10–39) 25 (10–38) 1.000 <0.001* 0.002*
HbA1c, mmol/mol
At diagnosis 36 (19–73) 33 (19–43) – <0.001*
At delivery 36 (21–56) 34 (21–41) – 0.003*
BMI: Body mass index, DM: diabetes mellitus, GDM: gestational diabetes mellitus, OGTT: oral glucose tolerance test, *: statistically significant.
Fig. 1. Prevalence of GDM in the cohort according to both criteria.













N 354 97 267 – – –
Treatment, n (%)
No treatment 9 (2.5) 5 (5.2) 228 (85.4) 0.320 <0.001* <0.001*
Diet and lifestyle advice 224 (63.3) 69 (71.1) 25 (9.4) 0.186 <0.001* <0.001*
Oral medication 11 (3.1) 1 (1.0) 2 (0.7) 0.322 0.049* 0.793
Insulin treatment 110 (31.1) 22 (22.7) 12 (4.5) 0.130 <0.001* <0.001*
Weeks of insulin treatment 8 (1–25) 7 (1–23) 3 (1–19) 0.428 0.111 1.000
PIH, n (%) 31 (8.8) 5 (5.2) 19 (7.1) 0.296 0.552 0.636
PE, n (%) 17 (4.8) 3 (3.1) 8 (3.0) 0.587 0.306 1.000
GA at delivery, weeks 38.7 (25.6 -41-3) 38.9 (25.6–41.3) 39.0 (19.0–41.7) 1.000 0.965 1.000
Mode of delivery, n (%)
Vaginal delivery 238 (67.2) 69 (71.1) 180 (67.4) 0.539 1.000 0.526
Primary cesarean delivery 76 (21.5) 18 (18.6) 55 (20.6) 0.575 0.843 0.768
Secondary cesarean delivery 41 (11.6) 10 (10.3) 33 (12.4) 0.602 0.904 0.714
Instrumental delivery 53 (15.0) 11 (11.3) 34 (12.7) 0.415 0.484 0.857
Indication for cesarean section, n (%)
Prolonged first stage of labor 28 (24.1) 5 (17.9) 16 (18.2) 0.619 0.390 1.000
Elective 49 (42.2) 12 (42.9) 35 (39.8) 1.000 0.775 0.827
Maternal indication 13 (11.2) 0 (0.0) 15 (17.0) 0.073 0.304 0.020*
Fetal indication 26 (22.4) 11 (39.3) 22 (25.0) 0.059 0.740 0.156
PIH: pregnancy induced hypertension, PE: pre-eclampsia, GA: gestational age, *: statistically significant.













N 354 97 267 – – –
Birth weight, g 3338 (800–4950) 3315 (800–4950) 3520 (138–5080) 1.000 0.014 0.010
SGA 32 (9.0) 10 (10.3) 22 (8.2) 0.844 0.775 0.676
LGA 48 (13.6) 11 (11.3) 49 (18.4) 0.615 0.118 0.150
Prematurity (<37 weeks), n (%) 40 (11.3) 8 (8.2) 30 (11.2) 0.461 1.000 0.447
Shoulder dystocia, n (%) 8 (2.3) 1 (1.0) 9 (3.4) 0.691 0.461 0.301
Hyperbilirubinemia requiring
phototherapy, n (%)
19 (5.4) 3 (3.1) 24 (9.0) 0.437 0.082 0.070
Neonatal hypoglycemia, n (%) 78 (22.0) 19 (19.6) – 0.677 – -*
Admission to NICU, n (%) 61 (17.2) 16 (16.5) 51 (19.1) 0.881 0.598 0.648
Birth defects, n (%) 39 (11.0) 11 (11.3) 22 (8.2) 1.000 0.278 0.409
Respiratory support, n (%) 16 (4.5) 7 (7.2) 15 (5.6) 0.299 0.579 0.620
Mortality, n (%)
Intra uterine 1 (0.3) 0 (0.0) 2 (0.7) 1.000 0.580 0.608
Neonatal 5 (1.4) 3 (3.1) 3 (1.1) 0.377 1.000 0.348
SGA: Small for gestational age, LGA: Large for gestational age, NICU: Neonatal intensive care unit, *: statistically significant. Neonatal glucose levels have been measured in 48
% of the cases in the WHO-2013 included group.
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(Table 3).
Of the newly included group, 76 women with an initially
negative OGTT according to WHO-1999 underwent a second OGTT,
as recommended for symptomatic women and women with a
history of GDM [7]. Of these women, 30 had a positive OGTT
according to the WHO-1999 criteria and were treated for GDM. The
second OGTT was done at a median of seven weeks later than the
first OGTT and a relatively large proportion of these women (37 %)
delivered a LGA neonate.
Discussion
This retrospective cohort study shows the impact on the
prevalence and pregnancy outcomes of GDM when shifting from
the WHO-1999 to the WHO-2013 criteria. Implementing the new
criteria results in a major increase in GDM prevalence, which is in
accordance to previous reports [11–14]. The newly included
women were more overweighed and delivered neonates with a
higher birth weight. In addition, the proportion of LGA neonates
tended to be higher in the newly included group. Previous studies
also have shown that women diagnosed with the revised criteria
are more likely to be overweighed [14,16].
In agreement with previous observations (15) our finding shows
that the added value of the fasting glucose of the WHO-1999 criteria
to diagnose GDM is disappointingly low as only 2 % of our patients
with GDM had a fasting plasma glucose level above the threshold
of 7.0 mmol/L. This finding is a strong argument for lowering the
fasting glucose threshold as recommended by the WHO-2013
criteria and results in a marked reduction in the number of OGTTs to
be performed, which not only is beneficial for the patient but also
saves costs. Indeed with application of the new diagnostic criteria an
OGTT could have been avoided in almost 80 % of our patients [15].
Women excluded by the WHO-2013 criteria had lower HbA1c levels
thanwomen in the WHO-1999 group, indirectly supporting the view
that exclusion of these women was appropriate.
The reason for a cesarean section was less often because of a
maternal indication in the WHO-2013 excluded group. This may
suggest that maternal comorbidities are less often prevalent in this
group, which is reasonable because of the lower BMI in this group
of excluded women.
The rate of neonatal hypoglycemia was hardly comparable since
the majority of the babies delivered in the WHO-2013 included
group did not have routinely glucose monitoring.Thirty-nine women with an initially undisturbed OGTT
according to WHO-1999 criteria were treated for GDM (Table 2).
In 30 of these women, treatment was started because of a
disturbed OGTT at a second occasion. The indication for the
treatment in the other nine women was a high random glucose
level. On the other hand, nine women, while having a disturbed
OGTT according to WHO-1999 criteria, were not treated for GDM
because they were diagnosed after 37 weeks gestation and
therefore delivery was chosen instead of starting treatment.
Neonates delivered by women with a delayed diagnosis and
hence a delay in treatment were more often large for gestational
age. These women were treated for a shorter amount of time. One
may wonder if the proportion of LGA and macrosomia would have
been lower if no delay in diagnosis had occurred, since appropriate
management of GDM is associated with a lower birth weight [6].
Indeed, Koning et al., have reported that treating women equally
for GDM based either on WHO-2013 or WHO-1999 criteria results
in a similar proportion of LGA neonates [17]. Since patients with
GDM according to the WHO-2013 criteria make up 22 % of all LGA
pregnancies, this might be an adequate endpoint for defining OGTT
threshold values [12].
In the WHO-1999 group 2.5 % of patients and in the WHO-2013
included group 85.4 % of patients were not treated for GDM.
Despite this large difference in treatment, almost no difference in
maternal or fetal/neonatal outcomes between these two groups
was observed. This absent difference in outcomes is likely
explained by the fact that with the OGGT screening the majority
of patients has a mild form of GDM as also reflected by the
relatively low HbA1c value.
Limitations
Not all data of all women could be collected from the patients’
records, related to the retrospective design of the study. Further-
more, the OGTT’s were carried out in women with one or more risk
factors for GDM. The prevalence of GDM found in our study is
therefore not a reflection of that in the general obstetric population.
Finally, women of the WHO-2013 included group were not
diagnosed with GDM and the majority of therefore not treated for
this condition, thereby limiting the comparison of outcomes
between this group and the WHO-1999 group. Of note, maternal
and fetal/neonatal outcomes between the WHO-1999 and the WHO-
2013 excluded group were comparable, probably for earlier
mentioned reasons. Neonatal glucose levels have been measured
18 M. Shareef et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 246 (2020) 14–18in 48 % of the cases in the WHO-2013 included group because GDM
was not diagnosed or treated in most patients of this group.
Conclusion
Implementing the new diagnostic criteria leads to a consider-
able increase in the prevalence of GDM, with the newly included
women being more frequently overweighed delivering babies with
a higher birth weight. The relatively high fasting glucose threshold
of the 1999-WHO criteria has a very low added value to diagnose
GDM, favoring the use of a lower fasting plasma glucose threshold
as advocated by the WHO-2013 criteria, thereby reducing the
number of OGTTs.
Prospective, randomized studies are needed to determine
whether the newly included women equally benefit from
treatment and whether women that will be excluded by the
new criteria could be safely left untreated.
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